Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Cytochrome P450 (P450) enzymes oxidize xenobiotics into chemically reactive metabolites or intermediates as well as into stable metabolites. If the reactivity of the product is very high, it binds to a catalytic site or sites of the enzyme itself and inactivates it. This phenomenon is referred to as mechanism-based inactivation. Many clinically important drugs are mechanism-based inactivators that include macrolide antibiotics, calcium channel blockers, and selective serotonin uptake inhibitors, but are not always structurally and pharmacologically related. The inactivation of P450s during drug therapy results in serious drug interactions, since irreversibility of the binding allows enzyme inhibition to be prolonged after elimination of the causal drug. The inhibition of the metabolism of drugs with narrow therapeutic indexes, such as terfenadine and astemizole, leads to toxicities. On the other hand, the fate of P450s after the inactivation and the toxicological consequences remains to be elucidated, while it has been suggested that P450s modified and degraded are involved in some forms of tissue toxicity. Porphyrinogenic drugs, such as griseofulvin, cause mechanism-based heme inactivation, leading to formation of ferrochelatase-inhibitory N-alkylated protoporphyrins and resulting in porphyria. Involvement of P450-derived free heme in halothane-induced hepatotoxicity and catalytic iron in cisplatin-induced nephrotoxicity has also been suggested. Autoantibodies against P450s have been found in hepatitis following administration of tienilic acid and dihydralazine. Tienilic acid is activated by and covalently bound to CYP2C9, and the neoantigens thus formed activate immune systems, resulting in the formation of an autoantibodydirected against CYP2C9, named anti-liver/kidney microsomal autoantibody type 2, whereas the pathological role of the autoantibodies in drug-induced hepatitis remains largely unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00003 · Cited by 908
Free heme toxicity and its detoxification systems in human
Kumar, S., & Bandyopadhyay, U. (2005) · Toxicology Letters · doi:10.1016/j.toxlet.2005.03.004 · Cited by 852
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796 · cited 5×
“…blocker (Figure 4), behaves as a mechanism-based inactivator of CYP3A4 (discussed earlier), leading to potent inhibition of the several drugs and resultant toxicities, including lifethreatening rhabdomyolysis in patients on lovastatin and simvastatin (Corsini et al., 1999; Krayenbuhl et al., 1999).”
BackgroundInfluentialKassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., & Baillie, T. A. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000180q · Cited by 311 · cited 1×
“…that reactive metabolites formed from oxidative cleavage of the common thiazolidinedione ring and/or a quinone methide formed from the troglitazone-specific chromane moiety, both of which have been identified as their GSH adducts (Kassahun et al., 2001), are involved in the inactivation of CYP3A4.”
BackgroundRole of Drug Disposition in Drug Hypersensitivity: A Chemical, Molecular, and Clinical Perspective
Park, B. K., Pirmohamed, M., & Kitteringham, N. R. (1998) · Chemical Research in Toxicology · doi:10.1021/tx980058f · Cited by 267 · cited 2×
“Immune-mediated mechanisms for drug toxicity, particularly hepatotoxicity, which is mediated by drug–protein adducts, are based on the “hapten hypothesis” (Griem et al., 1998; Park et al., 1998; Pohl et al., 1988).”
BackgroundAssessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450
Sai, Y., Dai, R., Yang, T. J., Krausz, K. W., Gonzalez, F. J., Gelboin, H. V., & Shou, M. (2000) · Xenobiotica · doi:10.1080/004982500237541 · Cited by 138
Clinically significant pharmacokinetic drug interactions with benzodiazepines
Tanaka, E. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00247.x · Cited by 52
Cited by
Kumar, B. S., Chung, B. C., Kwon, O., & Jung, B. H. (2012) · Journal of Applied Toxicology · doi:10.1002/jat.1746 · Cited by 52
Erve, J. C. L., Gauby, S., Maynard, J. W., Svensson, M. A., Tonn, G., & Quinn, K. P. (2013) · Chemical Research in Toxicology · doi:10.1021/tx4001144 · Cited by 48
Parker, J. E., Merkamm, M., Manning, N. J., Pompon, D., Kelly, S. L., & Kelly, D. E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00517-08 · Cited by 46
Metadata
- Authors
- Masubuchi, Y., & Horie, T.
- Venue
- Critical Reviews in Toxicology
- Publisher
- Informa UK Limited
- Published
- 2007-01
- Volume
- 37
- Issue
- 5
- Pages
- 389-412
- ISSN
- 0045-6446 (ISSN-L)
- 1040-8444
- 1547-6898
- OpenAlex
- W2130091396
- Cited by
- 95
- References
- 8
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs. https://app.cochat.ai/papers/10.1080/10408440701215233
- The paper
- Masubuchi, Y., & Horie, T. (2007). Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs. Critical Reviews in Toxicology. https://doi.org/10.1080/10408440701215233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.